4 results about "Manic Disorders" patented technology

Embodiments of the present invention relate generally to the treatment of schizophrenia or bipolar I disorder, and more particularly to the administration of iloperidone, including escalating doses of iloperidone, a pharmaceutically acceptable salt of iloperidone, an active metabolite of iloperidone, or a pharmaceutically acceptable salt of a metabolite of iloperidone, in such treatment. A first aspect of the present invention provides a method of treating a patient suffering from bipolar I disorder, comprising administering to the patient an effective amount of iloperidone, a pharmaceutically acceptable salt of iloperidone, an active metabolite of iloperidone, or a pharmaceutically acceptable salt of a metabolite of iloperidone, wherein the effective amount is effective to improve at least one manic symptom in the patient.

Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.

A method of treatment of mental disorder of a subject includes the steps of: normalizing an expression of both DRD1 and DRD5, which belong to DRD1-like family, of the subject to a preset standard level. The DRD1 / 5 level and expression can be increased or decreased bidirectionally by targeting an upstream promoter sequence of DRD1 / 5. The promoter activity of DRD1 / 5 can be attenuated by using an antipsychotic which directly targets the DRD1 / 5 promoter. The antipsychotics being used are typical and / or atypical antipsychotic medications such as Haloperidol,Risperidone, Clozapine and Cariprazine. The treatment is also useful for the subject with an impaired constitutive expression of DRD1 / 5 gene. The method can be used to treat schizophrenia, autism, depression, mania and bipolar disorders by normalizing the DRD1 / 5 expression level. The promoter gene sequencing of DRD1 and / or DRD5 can also be used for quantitative mental health screening through comparing with a standard sequence database.

The application discloses an amino thiazole compound and use thereof as a brain-permeable histamine H2 receptor agonist, and belongs to the field of medicines. The amino thiazole compound provided by the application has a structural general formula as shown in formula (I) and includes pharmaceutically acceptable salts. The amino thiazole compound has histamine H2 receptor agonistic activity and excellent blood-brain barrier permeability. Therefore, the amino thiazole compound can be applied to preparation of a medicine for treating diseases such as schizophrenia, mania, attention deficit hyperactivity disorder, binge eating or bulimia nervosa, autism, Parkinson's disease, ischemic brain injury and the like.